Literature DB >> 19307991

CD40-activated apoptotic tumor cell-pulsed dendritic cell could potentially elicit antitumor immune response: involvement of up-regulation of B7-H3 expression.

Cheng Chen1, Yi-Bei Zhu, Qiu-Xia Qu, Yan Ge, Jian-An Huang, Yong Wang, Xue-Guang Zhang.   

Abstract

Dendritic cells (DCs) initiate and direct immune responses. Previous in vitro and in vivo studies have showed that DCs matured with CD40 linking signal could potentially elicit and boost antitumor immunity, however, its molecular mechanism remain elusive. This study demonstrates that expression of B7-H3 on apoptotic cell-loading DCs is up-regulated markedly by CD40 activation but not by tumor necrosis factor-alpha stimulation. There was no significant difference found with CD40, CD80, or CD86 expressions when activated by CD40 or tumor necrosis factor-alpha stimulation. In tumor-bearing mice, T cells conditioned with B7-H3-blocked on CD40-activated apoptotic tumor cell-pulsed DCs had a decreased ability to inhibit tumor growth. Therefore, it is hypothesized that high levels of B7-H3 expression contributes to the ability of CD40-activated tumor associated DCs in eliciting efficient antitumor immune response, given this fact the potentially significant clinical implications, CD40-activated DCs merit further considerations when preparing DCs for clinical application.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19307991     DOI: 10.1097/CJI.0b013e31818c8816

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  2 in total

1.  Sensitization of SiHa cell to gemcitabine by CD40 activation and its overexpression in cervical carcinoma.

Authors:  Qin Huang; Qiu-Xia Qu; Fang Xie; Jian-Ming Hu; You-Guo Chen; Xue-Guang Zhang
Journal:  Med Oncol       Date:  2010-05-14       Impact factor: 3.064

2.  MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY.

Authors:  Therese Liechtenstein; Ines Dufait; Alessio Lanna; Karine Breckpot; David Escors
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2012-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.